Tardive Dyskinesia

The FDA has approved Austedo XR in four new tablet strengths for adults diagnosed with tardive dyskinesia and chorea associated with Huntington’s disease, according to the manufacturer.

The FDA has approved Ingrezza sprinkle capsules to treat adults with Huntington’s disease chorea or tardive dyskinesia, according to a press release from the manufacturer.

Adam Margolius, MD, neurology specialist at Cleveland Clinic discusses the impact that tardive dyskinesia on a patient's daily life and mental health.

Adam Margolius, MD, neurology specialist at Cleveland Clinic, discusses the greatest challenges patients and physicians face in tardive dyskinesia care.

Adam Margolius, MD, neurology specialist at Cleveland Clinic, emphasizes the need for patients who are on medications that block dopamine to be screened often by a healthcare professional, whether that be a primary care specialist, neurologist or psychologist.

Adam Margolius, MD, neurology specialist at Cleveland Clinic, highlights the current treatment options for patients with tardive dyskinesia as well the future of TD care.

Adam Margolius, MD, neurology specialist at Cleveland Clinic, discusses recent medications that have been effective in calming excessive movements caused by tardive dyskinesia.

The FDA has accepted a new drug application from Neurocrine Biosciences Inc. for its novel granule formulation of oral Ingrezza capsules, for those with tardive dyskinesia or chorea associated with Huntington’s disease.

Healio spoke with an expert psychiatrist on diagnosing, current treatment options, and the unmet needs of patients with tardive dyskinesia.

Healio spoke with an expert psychiatrist on diagnosing, current treatment options, and the unmet needs of patients with tardive dyskinesia.